---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-25-000099"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T21:45:13.077499+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Q1: INGREZZA $545M (+8%), CRENESSITY $14.5M; GAAP EPS $0.08; reaffirms FY25 guide

## Summary
- INGREZZA net product sales $545M in Q1 2025, up 8% YoY; CRENESSITY sales $14.5M with 413 patient enrollment forms.
- GAAP net income $7.9M ($0.08 EPS) vs $43.4M ($0.42) YoY; Non-GAAP net income $71.5M ($0.70) vs $124.8M ($1.20).
- Reaffirmed 2025 INGREZZA net sales guidance of $2.5-$2.6B; total R&D guidance $960M-$1.01B GAAP.
- Initiated Phase 3 registrational programs for osavampator in MDD and NBI-568 in schizophrenia.
- Appointed Sanjay Keswani, M.D., as Chief Medical Officer effective June 2, 2025; authorized $500M share repurchase, $150M completed.

## SEC filing metadata
- accession: 0000914475-25-000099
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447525000099/0000914475-25-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447525000099/nbix-20250505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-25-000099
- JSON: https://secwatch.observer/filing/0000914475-25-000099.json
- Plain text: https://secwatch.observer/filing/0000914475-25-000099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.